GlaxoSmithKline is to make public the level of advisory fees it offers to doctors and medical academics, and will strictly cap the payments they can receive in the US to $150,000 (£88,000) a year each.
Andrew Witty, chief executive of the UK-based pharmaceutical company, said he was introducing tougher new rules to impose a cap "without exception" on such payments and promised to publish the amounts.
His commitment comes at a time of growing concern that the widespread practice of payments by pharmaceutical companies may help unfairly influence "key opinion leaders" (KOLs) in the medical community, in a way that biases their judgments and recommendations for particular treatments.
1 comment:
CEO Andrew Witty told the FT, “In the past, whatever has happened has happened...."
Priceless $$$$ quote
Post a Comment